Last Week Akorn, Inc. (NASDAQ:AKRX) Ratings

April 16, 2018 - By Russell Jones

Akorn, Inc. (NASDAQ:AKRX) Ratings Coverage

Total analysts of 6 have positions in Akorn (NASDAQ:AKRX) as follows: 0 rated it a “Buy”, 0 with “Sell” and 6 with “Hold”. The positive are 0. Since October 20, 2017 according to StockzIntelligence Inc Akorn has 7 analyst reports. On Thursday, March 15 Susquehanna maintained the shares of AKRX in report with “Hold” rating. On Friday, October 27 Jefferies maintained Akorn, Inc. (NASDAQ:AKRX) with “Hold” rating. On Sunday, November 5 the stock has “Hold” rating by RBC Capital Markets. On Friday, October 20 the rating was maintained by Piper Jaffray with “Hold”. The company rating was maintained by William Blair on Wednesday, February 28. On Thursday, March 29 the firm has “Hold” rating given by RBC Capital Markets. Listed here are Akorn, Inc. (NASDAQ:AKRX) PTs and latest ratings.

29/03/2018 Broker: RBC Capital Markets Rating: Hold New Target: $25.0000 Maintain
15/03/2018 Broker: Susquehanna Rating: Hold New Target: $20.0 Maintain
28/02/2018 Broker: William Blair Rating: Hold Maintain
22/02/2018 Broker: Deutsche Bank Rating: Hold New Target: $34.0
05/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $34.0 Maintain
27/10/2017 Broker: Jefferies Rating: Hold New Target: $34.0 Maintain
20/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $34.0 Maintain

On during the last trading session the stock increased $0.26 or 1.41%, reaching $18.69.Currently Akorn, Inc. is downtrending after 20.35% change in last April 16, 2017. AKRX has 685,695 shares volume. AKRX underperformed the S&P500 by 31.90%.

Akorn, Inc., a specialty generic pharmaceutical company, develops, makes, and markets specialized generic and branded pharmaceuticals, over-the-counter drug products, and animal health products in the United States and internationally.The firm is worth $2.34 billion. The firm operates in two divisions, Prescription Pharmaceuticals and Consumer Health.Last it reported negative earnings. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics.

Akorn, Inc. (NASDAQ:AKRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.